Keep the corners; adriamycin nephropathy

Implication for health policy/practice/research/medical education: Adriamycin is an anticancer agent with broad-spectrum efficacy against tumors. However, chemotherapy-induced renal toxicity constraints clinical efficacy of cancer treatment. The nephropathy of adriamycin is detected by podocyte damage and foot process effacement, which followed by glomerulosclerosis and inflammation in the tubulointerstitial area and fibrosis.